期刊
CURRENT OPINION IN PHARMACOLOGY
卷 34, 期 -, 页码 36-48出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2017.04.002
关键词
-
资金
- Medical Research Council
- Muscular Dystrophy UK
- Duchenne UK
- Therapeutics plc
- Medical Research Council [MR/N010698/1, G0801763] Funding Source: researchfish
- Muscular Dystrophy UK [RA3/3073] Funding Source: researchfish
- MRC [G0801763, MR/N010698/1] Funding Source: UKRI
Duchenne muscular dystrophy (DMD) is a lethal, X-linked muscle-wasting disease caused by lack of dystrophin, essential for muscle fibre integrity. Despite extensive pre-clinical studies, development of an effective treatment has proved challenging. More recently, significant progress has been made with the first drug approval using a genetic approach and the application of pharmacological agents which slow the progression of the disease. Drug development for DMD has mainly used two strategies: (1) the restoration of dystrophin expression or the expression of the compensatory utrophin protein as an efficient surrogate, and (2) the mitigation of secondary downstream pathological mechanisms. This review details current most promising pharmacological approaches and clinical trials aiming to tackle the pathogenesis of this multifaceted disorder.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据